ABT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Abbott Laboratories (ABT) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has strong long-term growth potential, recent financial performance, lowered guidance, and negative technical indicators suggest waiting for a more favorable entry point.
The stock is currently in a bearish trend with the MACD histogram at -0.219 and negatively expanding, RSI_6 at 17.541 indicating oversold conditions, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The stock closed at $95.4, below the key pivot level of $99.663, with support at $95.876 and resistance at $103.451.
Healthcare stocks, including Abbott, have shown resilience during economic downturns.
The company lowered its 2026 adjusted EPS forecast to $5.38–$5.58, causing a 6% drop in stock price. Net income and EPS dropped significantly YoY in Q1 2026, and gross margin slightly declined. Analysts have been lowering price targets, and technical indicators suggest bearish momentum.
In Q1 2026, Abbott's revenue increased by 7.78% YoY to $11.16 billion, but net income dropped by 18.72% YoY to $1.08 billion, and EPS fell by 18.42% YoY to $0.62. Gross margin declined slightly to 52.51%.
Analysts maintain generally positive ratings (Outperform/Buy), but several firms have lowered price targets recently due to lowered guidance and underwhelming financial results. Current price targets range from $120 to $144.
